Market news

University of Szeged installed Hungary’s first Robotic Magnetic Navigation system in JulyOver 70 patients with all forms of arrhythmia treated robotically to date, a record pace of use globallyRobotics enabled successful treatment of patients with multiple previously failed ablation proceduresUniversity of Szeged to celebrate leadership in technology and grand opening of Robotic Cardiology Program at upcoming scientific symposium on September 8th ST. LOUIS, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Ste

Moby summary of Stereotaxis, Inc.'s Q2 2026 earnings call

Stereotaxis (NYSEAMERICAN:STXS) reported second-quarter 2026 revenue of $7.7 million, as growth in sales of its robotic catheter portfolio helped lift recurring revenue to a multiyear high despite lower system revenue and continued supply constraints. Revenue declined from the prior-year quarter be

Stereotaxis (STXS) delivered earnings and revenue surprises of -66.67% and -19.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Robotic catheter revenue surpasses $1M in the quarter, growing 270% sequentiallyFirst GenesisX robotic system purchase by US hospital to be installed this fallMultiple Synchrony digital operating room systems sold and installed following FDA clearance in AprilCompleted previously announced acquisition of Robocath, strengthening robotic technology leadership across the full spectrum of endovascular procedures ST. LOUIS, Mo., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer an

ST. LOUIS, July 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2026 second quarter on Tuesday, August 11, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments. What:Stereotaxis second quarter

Assessing Stereotaxis Shelf Registrations and Capital Flexibility Stereotaxis (STXS) has filed multiple shelf registrations that would allow the company to offer up to 128,317,934 common shares, totaling roughly US$205.3 million, putting potential capital raising and dilution firmly on investors radar. See our latest analysis for Stereotaxis. Stereotaxis shares closed at US$1.55 after a sharp 1 day share price decline of 6.06%, extending a year to date share price fall of 33.19% and a 1 year...